|
PRESSEMITTEILUNGEN
March 2, 2010
Lux Biosciences Receives Acceptance of Luveniq™ MAA Filing from European
Medicines Agency
February 4, 2010
Lux Biosciences Files for LUVENIQ™ Approval in US and Europe for
Noninfectious Uveitis
November 16, 2009
Lux Biosciences to Present at Lazard Capital Markets 6th Annual
Healthcare Conference
October 26, 2009
Potential of Lux Biosciences’ LUVENIQ (LX211) as First Disease Modifying
Treatment for Sight-Threatening Non-Infectious Uveitis Highlighted at
American Academy of Ophthalmology
October 20, 2009
Lux Biosciences Announces Multiple Presentations on LX211 at Upcoming
American Academy of Ophthalmology and American Uveitis Society Annual
Meetings
October 19, 2009
Lux Biosciences Completes $50 Million Series B Financing
September 23, 2009
Lux Biosciences Reports Phase 1 Safety Results and Open Label Efficacy
Results for LX214, a Potential Best-in-Class Treatment for Dry Eye
September, 8, 2009
Lux Biosciences to Present at the Thomas Weisel Partners Health Care
Conference
May 26, 2009
Lux Biosciences’ Luveniq™ (LX211) Highlighted at International
Conference on Ocular Inflammation
May 4, 2009
First Oral Drug for Uveitis Reduces Both Inflammation and Recurrence
Rate in Potentially Blinding Eye Disease, Reports Lux Biosciences
March 26, 2009
Lux Biosciences Reports Positive Results from LUMINATE
Phase 3 Program of LX211 (LUVENIQ™) in Uveitis
March 18, 2009
Lux Biosciences Completes Patient Enrollment in LUCIDA Phase 3 Program
for Prevention of Corneal Transplant Rejection
February 17, 2009
Lux Biosciences Initiates Phase 1 Study of LX214, a Development
Candidate for Dry Eye Syndrome
November 26, 2008
Lux Biosciences Announces European Medicines Agency Acceptance
of Its Pediatric Investigation Plan for LUVENIQ™
November 11, 2008
Lux Biosciences to Present at Lazard Capital Markets 5th Annual
Healthcare Conference
September 11, 2008
Lux Biosciences’ Investigational Therapy for Uveitis, Luveniq™,
to be Featured at 7th International Symposium on Uveitis
August 12, 2008
Lux Biosciences Names Paul Chaney, Former President (OSI) Eyetech
and EVP OSI Pharmaceuticals, to Board of Directors
July 31, 2008
Lux Biosciences Presents Preclinical Data Demonstrating Potential of
LX214
as Best-in-Class Topical Treatment for Chronic Inflammatory Diseases of the
Eye
June 25, 2008
Lux Biosciences Completes Enrollment in LUMINATE
Pivotal Trial Program for Novel Uveitis Therapy, LUVENIQ™
June 19, 2008
Lux Biosciences Names Brett Skolnik Chief Financial Officer
June 18, 2008
Lux Biosciences to Present at Jefferies 2nd Annual Healthcare Conference
April
28, 2008
Lux Biosciences’ Presentations at ARVO Highlight
Both Topical and Polymer
Delivery Technologies Targeting Chronic Inflammatory Ocular Diseases
April
24, 2008
Lux Biosciences Reports on Pivotal Programs in
Uveitis
and Corneal Transplant Rejection at ARVO Meeting
February
26, 2008
Lux Biosciences to Provide Update on Four Pipeline Programs,
Including Two Phase 3 Clinical Programs, at ARVO
February 4, 2008
Lux Biosciences to Present at BIO CEO & Investor Conference
2008
January
30, 2008
Lux Granted Fast Track Designation For LX201 For
Corneal Transplant Rejection
November 20, 2007
Lux Biosciences to Present at Upcoming Investor
Conferences
October 29, 2007
Lux Biosciences To Present at Acumen Biofin
Rodman & Renshaw 9th Annual Healthcare Conference
September 17, 2007
Lux Biosciences to Present at 2007
UBS Global Life Sciences Conference
August 30, 2007
Novel
Steroid Sparing Strategies for the Treatment
of Uveitis and Prevention of Corneal Transplant Rejection to be Subject of
International Symposium Sponsored by Lux Biosciences
August 7, 2007
Lux Granted Fast Track Designation by
FDA for
LX211 for The Treatment of Uveitis
July 31, 2007
EMEA Committee for
Orphan Medicinal Products Recommends Orphan Medicinal
Product Designation for
Lux
Biosciences’ LX 211 for The Treatment of Uveitis
June 20, 2007
Lux Biosciences to Present at Jefferies Healthcare Conference
May 22, 2007
Lux
Biosciences Expands Biomaterials Technology
License
from Rutgers
University for Controlled
Ocular Delivery of Pharmaceuticals
May 4, 2007
Lux Biosciences’ Investigational Therapy for Uveitis, LX211,
is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
April 4, 2007
Lux Biosciences Initiates Clinical Trials of Its Second Pivotal Stage
Program
March 8, 2007
Lux
Biosciences to Present at Cowen & Company 27th Annual Health Care Conference
February 20, 2007
Lux
Biosciences Initiates LUMINATE Pivotal Clinical Trials of Its
Next-Generation Calcineurin Inhibitor,
LX211, in Uveitis
January 15, 2007
Lux Biosciences Receives Orphan Drug Designation from the FDA For Two
Ophthalmic Products
November 28, 2006
Lux
Biosciences Receives FDA Clearance for LX211 IND
November 7, 2006
Lux
Biosciences Announces Exclusive Worldwide License Agreement with NIH for
Late Stage Ophthalmic Product
September 18, 2006
Lux
Biosciences Establishes European-Based Operations
September 13, 2006
Lux Biosciences Gains Exclusive
Worldwide License
for Polyarylate Patent Estate from Rutgers University
for Ophthalmic Use
July 19, 2006
Lux Biosciences Increases Its Series A Venture Financing
by $13 Million, Bringing the Total Round to $49
Million; Dr. David Schnell of
Prospect Venture Partners
Joins Lux Biosciences' Board
July 11, 2006
Lux Biosciences Appoints
to Board of
Directors David Guyer,
SVLS Venture Partner and Former CEO of Eyetech
May 25, 2006 (2)
Isotechnika Signs Agreement Granting Lux
Biosciences Worldwide Ophthalmic Rights To ISA247
May 25, 2006 (1)
Lux Biosciences Raises $36 Million in Series A Financing
and
Signs Agreement for Advanced Clinical Stage Product
|
